Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

Launched by IAN J. NEELAND, MD · Jun 27, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes," is focusing on finding safer treatment options for older adults with type 2 diabetes. Sulfonylureas are medications commonly used to lower blood sugar, but they can cause serious problems like low blood sugar, falls, and heart risks, especially in older patients. The trial aims to encourage conversations between patients and their doctors about the risks of sulfonylureas and explore newer, safer medications that might be better options.

To participate in this study, you should be at least 45 years old, diagnosed with type 2 diabetes before the end of 2021, and currently taking sulfonylureas. If you join the trial, you will receive support to help you discuss your medication with your healthcare provider, and you may be part of a group that gets specific questions to ask or a general brochure about diabetes medications. The researchers will track how many patients engage in these discussions, whether they stop using sulfonylureas, and how well their diabetes and heart risks are managed. This study is important because it could lead to safer diabetes care for older adults across the country.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 45 years
• • Type 2 diabetes (diagnosed on or before 12/31/2021)
• • Current/active prescription for one or more SU medications
• • Established care (≥2 visits) with UH primary care provider (PCP) since 2021
• Exclusion Criteria:
• • Type 1 diabetes
• • PCP provides a reason why patient participation is inappropriate (e.g., known cost barriers without any alternatives, prior discussion with patient about alternatives, etc.)
• • Patient unable or unwilling to have conversation with their PCP regarding SU
• • Unable to provide informed consent